Alzheimers Research & Therapy

Article	Citations
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	171
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	166
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	131
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	122
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	119
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	106
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	105
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status	100
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	98
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	94
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	93
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	93
Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data	87
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	80
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	76
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	75
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	75
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	74
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	70
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	67
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	67
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	65
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	64
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217	61
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	61

Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis	60
Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer’s disease continuum in the prospective COGICARE study	56
Dementia risk communication. A user manual for Brain Health Services—part 3 of 6	55
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	55
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease	55
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog	52
Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study	52
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients	51
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	51
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	50
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease	50
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC	49
Serum neurofilament light chain level as a predictor of cognitive stage transition	49
Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts	49
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study	49
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease	49
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	48
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	48
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia	48
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort	48
Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study	48
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	47
Cross-cultural effects of reminiscence therapy on life satisfaction and autobiographical memory of older adults: a pilot study across Mexico and Spain	47
Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease	46
Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease	46
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies	45
Quantification of identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy with machine learning: a post hoc analysis of a diagnostic trial and validation of a	44
The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP	44
Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort	44
Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer’s continuum	43
White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia	42
Elevated Aβ aggregates in feces from Alzheimer’s disease patients: a proof-of-concept study	41
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individ	41
Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders	40
Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach	39
Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology	39
The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults	39
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study	38
Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease	38
Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study	38
Sex-specific risk factors and clinical dementia outcomes for white matter hyperintensities in a large South Korean cohort	38
Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer’s disease	38
Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer’s disease continuum: biological and methodological perspectives from disease heterogeneity	38
Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia	37
Divergent brain regional atrophy and associated fiber disruption in amnestic and non-amnestic MCI	37
The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer’s disease	37
Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?	37
Perivascular space enlargement accelerates in ageing and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study	36
VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome	36
Pathological correlates of impaired self-awareness of memory function in Alzheimer’s disease	35

Association of peripheral immunity with cognition, neuroimaging, and Alzheimer’s pathology	35
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease	35
Dementia with Lewy bodies and gait neural basis: a cross-sectional study	35
Distinct effects of blood pressure parameters on Alzheimer’s and vascular markers in 1,952 Asian individuals without dementia	35
Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change	34
Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia	34
Associations of resting heart rate with incident dementia, cognition, and brain structure: a prospective cohort study of UK biobank	34
Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort	34
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases	34
Nanoscale alterations in GABAB receptors and GIRK channel organization on the hippocampus of APP/PS1 mice	33
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration	33
Social frailty and its association with cognitive trajectories in older adults: a prospective cohort study	33
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxy	33
Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy	33
Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals	33
Synaptic protein CSF levels relate to memory scores in individuals without dementia	32
Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project	32
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	32
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease: a natural language processing study	32
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform	32
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2	31
PACAP–Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer’s disease	31
Alzheimer’s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline	28
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease	28
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disea	28
18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	27
Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults	27
Multi-omics analyses identify gut microbiota-fecal metabolites-brain-cognition pathways in the Alzheimer’s disease continuum	27
Letter to the Editor Authors’ Response: Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study	27
The associations of herpes simplex virus and varicella zoster virus infection with dementia: a nationwide retrospective cohort study	27
Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database	26
Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer’s disease	26
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease	26
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis	26
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials	26
The apolipoprotein receptor LRP3 compromises APP levels	26
Association of midlife body-weight variability and cycles with earlier dementia onset: a nationwide cohort study	26
Quantitative estimate of cognitive resilience and its medical and genetic associations	25
β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis	25
Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer’s disease	25
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data	25
REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals	25
Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients	25
Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals	25
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment	25
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease	25
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease	24
How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer’s disease risk? A novel integrative model	24
Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I-UDSNB 1.0): development and normative data	24
Cognitive impairment indicator for the neuropsychological test batteries in the Canadian Longitudinal Study on Aging: definition and evidence for validity	24
Subclinical carotid artery atherosclerosis and cognitive function in older adults	24
In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease	24
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	23
Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice	23
Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer’s dementia	23
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease	23
Methodological quality of systematic reviews on treatments for Alzheimer’s disease: a cross-sectional study	23
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease	23
Towards a national registry for Alzheimer’s disease and related dementias: rationale, design, and initial observations of the ABOARD cohort	23
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment	23
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein	22
Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer’s disease in TgF344-AD rats	22
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology	22
Circular RNA APP contributes to Alzheimer’s disease pathogenesis by modulating microglial polarization via miR-1906/CLIC1 axis	22
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy	22
Apolipoprotein E and sex modulate fatty acid metabolism in a prospective observational study of cognitive decline	22
Verbal intelligence is a more robust cross-sectional measure of cognitive reserve than level of education in healthy older adults	22
A polygenic risk score for Alzheimer’s disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S.	22
Correction to: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis	22
Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia	22
The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment	22
Alteration of medial temporal lobe metabolism related to Alzheimer’s disease and dementia with lewy bodies	22
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study	21
The course of primary progressive aphasia diagnosis: a cross-sectional study	21
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6	21
The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study	21
Purpose in life promotes resilience to age-related brain burden in middle-aged adults	21
Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease	21
Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment	21
Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease	20

High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 × Tg) mouse model of Alzheimer’s disease associated with chronic platelet activation	20
Diabetes status, duration, and risk of dementia among ischemic stroke patients	20
Alzheimer’s polygenic risk scores, APOE, Alzheimer’s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years	20
Optimizing midlife metabolic syndrome thresholds for dementia: a prospective study of two UK population-based cohorts	20
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum	20
Correction: Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study	20
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease	20
Prodromal frontotemporal dementia: clinical features and predictors of progression	20
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort	20
The presence of circulating human apolipoprotein J reduces the occurrence of cerebral microbleeds in a transgenic mouse model with cerebral amyloid angiopathy	20
Anticipatory reaching motor behavior characterizes patients within the Alzheimer’s disease continuum in a virtual reality environment	20
Molecular insights into sex-specific metabolic alterations in Alzheimer’s mouse brain using multi-omics approach	19
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis	19
The effects of a moderate physical activity intervention on physical fitness and cognition in healthy elderly with low levels of physical activity: a randomized controlled trial	19
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly	19
Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults	19
Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials	19
Exploring sex differences in Alzheimer’s disease: a comprehensive analysis of a large patient cohort from a memory unit	19
Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study	19
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants	19
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease	19
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review	18
Frontotemporal structure preservation underlies the protective effect of lifetime intellectual cognitive reserve on cognition in the elderly	18
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort	18
Correction: Italian adaptation of the Uniform Data Set Neuropsychological Test Battery (I‑UDSNB 1.0): development and normative data	18
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort	18
Correction: Abdominal obesity and the risk of young-onset dementia in women: a nationwide cohort study	18
Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status	18
Longitudinal validation of cognitive reserve proxy measures: a cohort study in a rural Chinese community	17
Insomnia, early and late rising are associated with small hippocampal volume and large white matter hyperintensity burden	17
Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer’s Disease	17
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways	17
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial	17
Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation	17
Soluble SorLA in CSF, a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer disease	17
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217	17
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease	17
Intermittent hypoxia training enhances Aβ endocytosis by plaque associated microglia via VPS35-dependent TREM2 recycling in murine Alzheimer’s disease	17
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk	17
Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging	17
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia	17
Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults	17
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns	17
Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint	17
Is later-life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post-mortem human brain tissue?	16
White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition	16
Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors	16
Perivascular space and white matter hyperintensities in Alzheimer’s disease: associations with disease progression and cognitive function	16
Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial	16
Network dynamics-based subtyping of Alzheimer’s disease with microglial genetic risk factors	16
Associations of computer gaming with incident dementia, cognitive functions, and brain structure: a prospective cohort study and Mendelian randomization analysis	16
Development and validation of a novel predictive model for dementia risk in middle-aged and elderly depression individuals: a large and longitudinal machine learning cohort study	16
Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic	16
Rotation errors in path integration are associated with Alzheimer’s disease tau pathology: a cross-sectional study	16
P2X7 receptor inhibition ameliorates ubiquitin–proteasome system dysfunction associated with Alzheimer’s disease	16
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	16
Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer’s disease? A 2-year longitudinal study	16
Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer’s disease	16
Correction: Diagnostic performance of plasma pTau217, pTau181, Aβ1‑42 and Aβ1‑40 in the LUMIPULSE automated platform for the detection of Alzheimer disease	16
Subjective cognitive decline predicts longitudinal neuropsychological test performance in an unsupervised online setting in the Brain Health Registry	16
Response to Schmidt et al.: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	16
Biophysical models applied to dementia patients reveal links between geographical origin, gender, disease duration, and loss of neural inhibition	16
The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic	16
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab	15
N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: insights into the therapeutic potential of neuronal and microglial NMDA rece	15
Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status	15
BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease	15
Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review	15
Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status	15
Stress, depression, and risk of dementia – a cohort study in the total population between 18 and 65 years old in Region Stockholm	15
Identification of profiles associated with conversions between the Alzheimer’s disease stages, using a machine learning approach	15
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease	15
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults	15
Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease	15
Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact	15
Amyloid-PET imaging predicts functional decline in clinically normal individuals	15
Older adults at greater risk for Alzheimer’s disease show stronger associations between sleep apnea severity in REM sleep and verbal memory	14
Herpes zoster and long-term risk of subjective cognitive decline	14
Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly	14
β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease	14
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease	14
Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer’s disease	14
Association between retinal microvascular abnormalities and late-life brain amyloid-β deposition: the ARIC-PET study	14
Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice	14
Intracranial internal carotid artery calcification is not predictive of future cognitive decline	14
APOE ε4, Alzheimer’s disease neuropathology and sleep disturbance, in individuals with and without dementia	14
Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases	14
Beyond expectations: investigating nilotinib’s potential in attenuating neurodegeneration in Alzheimer’s disease	14
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease	14
The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia	14
Understanding factors associated with the trajectory of subjective cognitive complaints in groups with similar objective cognitive trajectories	13
The behavioral variant of Alzheimer’s disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex	13
A digitally supported multimodal lifestyle program to promote brain health among older adults (the LETHE randomized controlled feasibility trial): study design, progress, and first results	13
Correction: γ‑Secretase modulator resistance of an aggressive Alzheimer‑causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds	13
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum	13